论文部分内容阅读
目的探讨低分子肝素钙联用奥扎格雷钠治疗不稳定型心绞痛(UAP)的疗效。方法将160例UAP患者随机分为治疗组和对照组各80例,治疗组采用低分子肝素钙联用奥扎格雷钠治疗,对照组应用常规治疗。结果治疗组74例心绞痛得到控制,控制率为91.3%;对照组60例得到控制,控制率为75%。两组相比差异有统计学意义。而不良反应发生率差异无统计学意义。结论低分子肝素钙联用奥扎格雷钠治疗UAP疗效好,不良反应轻微,是安全可靠的治疗方法。
Objective To investigate the curative effect of low molecular weight heparin combined with ozagrel sodium in the treatment of unstable angina pectoris (UAP). Methods 160 patients with UAP were randomly divided into treatment group and control group of 80 cases, the treatment group with low molecular weight heparin calcium combined with ozagrel sodium, the control group of conventional treatment. Results In the treatment group, 74 cases of angina pectoris were controlled with the control rate of 91.3%. The control group of 60 cases were controlled with the control rate of 75%. The difference between the two groups was statistically significant. The incidence of adverse reactions was no significant difference. Conclusion low molecular weight heparin calcium combined with ozagrel sodium in the treatment of UAP has good curative effect with minor adverse reactions and is a safe and reliable treatment.